The Observation Of Short-Term Efficacy In Combined Therapy With Docetaxel And Nedaplatin Or Gemcitabine And Nedaplatin In First Treatment Of Advanced Non-small Cell Lung Cancer

Objective: Nowadays Lung cancer has become the leading cause of cancer- related deaths. Among this non-small cell lung cancer (NSCLC) occupies the most proportion.The prognosis of non-small cell lung cancer is hard and the survival is short. To detect the efficacy and the side effect of the regimen for Docetaxel Combined with Nedaplatin and Gemcitabine with Nedaplatin Chemotherapy in the First Treatment of Advanced Non-small Cell Lung Cancer. Methods: A total of 77 patients with advanced non-small cell lung cancer were divided into the Docetaxel Combined with Nedaplatin group (n=40) and the Gemcitabine with Nedaplatin group (n=37). In the group of Docetaxel Combined with Nedaplatin , Docetaxel was administrated at the dose of 75mg/m2 on day 1. Nedaplatin was administrated at the dose of 80 mg/m2, on day 2. In group of Gemcitabine with Nedaplatin, Gemcitabine was administrated at the dose of 1.0g/m2 on day 1, 8;Nedaplain was administrated at the dose of 80 mg/m2 on day 2.Before the treatment the 5-HT3 rivalry was used in both group.The cycle was 21-day. We evaluate the curative effect after every two cycles. Results: The efficacy of group Docetaxel Combined with Nedaplatin was 52.50% and group of Gemcitabine with Nedaplatin was 40.54%. there was no significant difference between the two groups in curative effec(t P>0.05).A lower response rate of thrombocytopenia (47.5%)occurred in group of Docetaxel Combined with Nedaplatin , compared to that occurred in group of Gemcitabine with Nedaplatin (83.78%), with a significant difference between the two groups (P<0.01).There was no significant difference between two groups in the incidence of leucopenia response rate (87.5%)in group of Docetaxel Combined with Nedaplatin than in group of Gemcitabine with Nedaplatin (94.59%),with no significant difference between the two groups (P>0.05). There were no toxicity with kidney and heart in two groups。Conclusions: There is no significant difference of efficiency between Docetaxel Combined with Nedaplain group and Gemcitabine with Nedaplatin group. And the main adverse reaction was myelosuppression, especially thrombocytopenia. So during our clinical work ,we can choose the different treatment in different patients.